Phase 3
N=225
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease
Obstructive Sleep Apnea · Stroke · Transient Ischemic Attack · Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT00984308 ↗Enrolled (actual)
225
Serious AEs
3.1%
Results posted
Sep 2015
Primary outcome: Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA) (Procedure)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Sep 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sleep Apnea Diagnosis Rate |
58; 5 | — |
| PRIMARY Hypertension Control |
157.4; 161.6 | — |
| SECONDARY Sleep Apnea Treatment Rate |
22; 0 | — |
Summary
Sleep apnea is common among Veterans with cerebrovascular disease (stroke or transient ischemic attack [TIA]), leads to hypertension, and is associated with recurrent stroke and death. Although continuous positive airway pressure (CPAP) safely treats sleep apnea, few Veterans with cerebrovascular disease are diagnosed with sleep apnea or offered treatment.
Eligibility Criteria
Inclusion Criteria
Stroke or Transient Ischemic Attack Hypertension
Exclusion Criteria
- Prior diagnosis of sleep apnea or other sleep disorder
- Life expectancy < 6 months or Hospice
- Non-English speaker
- Unable/unwilling to use mask
- Inability to give informed consent
- Oxygen dependent COPD
- Chronic renal failure with dialysis
- Active Suicidal Ideation
Data sourced from ClinicalTrials.gov (NCT00984308). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.